COG.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:12):

Stats
Dzisiejszy wolumen	72 239.00
Średni wolumen	60 988.00
Kapitalizacja rynkowa	17.01M
EPS	£0 ( 2024-05-01 )
Następna data zysków	( £0 ) 2024-06-27
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-4.85
ATR14	£0.217 (0.44%)

Cambridge Cognition Korelacja

10 Najbardziej pozytywne korelacje
PIN.L	0.922
ICGT.L	0.917
WBI.L	0.913
SGZ.L	0.911
IQE.L	0.909
AMGO.L	0.906
NAIT.L	0.905
GROW.L	0.903
KRPZ.L	0.902
XRH0.L	0.901

10 Najbardziej negatywne korelacje
BA.L	-0.918
FCCN.L	-0.911
WPS.L	-0.911
TIP5.L	-0.9
COST.L	-0.899
IL0A.L	-0.898
RSG.L	-0.897
VPAC.L	-0.896
KOO.L	-0.894
CATC.L	-0.892

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cambridge Cognition Finanse

Annual	2022
Przychody:	£12.61M
Zysk brutto:	£9.32M (73.91 %)
EPS:	£-0.0131

FY	2022
Przychody:	£12.61M
Zysk brutto:	£9.32M (73.91 %)
EPS:	£-0.0131

FY	2021
Przychody:	£10.09M
Zysk brutto:	£8.08M (80.04 %)
EPS:	£0.00563

FY	2020
Przychody:	£6.74M
Zysk brutto:	£5.42M (80.36 %)
EPS:	£-0.0150

Financial Reports:

No articles found.

Cambridge Cognition

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online trial recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases IIV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and NeuroVocalix for an automated administration and scoring of well-validated verbal cognitive assessments?on a secure platform. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.